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5VISION STATEMENT
A world without vaccine preventable 
disease, disability, and death. 
MISSION STATEMENT
To protect the health of Americans 
and global citizens by preventing 
disease, disability, and death through 
immunization. 
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7BACKGROUND
AND INTRODUCTION
Childhood immunization is one of the most cost-effective of all health 
interventions.  In the past two decades, immunization has prevented 
an estimated 20 million deaths globally from vaccine-preventable 
diseases.  
The United States has greatly reduced its burden of vaccine-
preventable diseases (VPDs) through childhood immunization. 
However, U.S. children and adults remain at risk for VPDs largely 
due to their widespread occurrence in other countries. Globally, 
more than 2 million childhood deaths from VPDs are prevented each 
year (2004 estimate), and an additional 600,000 hepatitis B-related 
deaths from liver cirrhosis and hepatoma that may otherwise have 
occurred in adulthood are prevented.    
Each year, more than 130 million children are born worldwide who 
need immunization services.  While 78% of the world’s infants receive 
diphtheria-tetanus-pertussis vaccine (DTP3) – the benchmark 
indicator of annual routine immunization coverage – an estimated 
27 million infants remain unvaccinated.   One in six children is not 
vaccinated against tuberculosis; 1 in 4 is not vaccinated against 
measles, only half of the world’s infants are fully immunized against 
hepatitis B, and 3 in 4 are not vaccinated against Hib disease. 
The negative impact of these gaps in immunization is enormous.  An 
estimated 1.4 million children under age ﬁve died from the six major 
VPDs in 2004, with a further 1.1 million deaths from pneumococcal 
disease and rotavirus (vaccines that are available in the United States 
but rarely used in developing countries).  
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support for polio eradication and measles elimination.  CDC’s yearly 
investment in global immunization has grown from $3.1 million to 
$140 million in 2006.  In addition, CDC currently has more than 30 
staff seconded to international health organizations, such as WHO, 
UNICEF, Pan American Health Organization, World Bank, and the 
American Red Cross, providing full-time technical and operational 
support to priority countries and regions.  
In keeping with this growth, CDC has a much broader role and 
greater inﬂuence in the ﬁeld of global immunization than it did even 
ﬁve years ago.  In addition to being a key partner in both the global 
polio eradication initiative and the Measles Initiative, CDC has played 
a critical role in developing the Global Immunization Vision and 
Strategy for 2006-2015 (GIVS); has a representative on the Global 
Alliance for Vaccines and Immunization (GAVI) working group; is 
an implementing partner in the Hib Initiative, charged by the GAVI 
Alliance to assist countries to make evidence-based decisions 
regarding the introduction of Hib vaccine into national programs; 
and is supporting pilot projects in three countries to strengthen the 
delivery of routine immunization.   
In addition, since CDC’s last ﬁve-year strategic plan for global 
immunization, much has changed.  There has been a renewed 
commitment from global partners for preventing VPDs among the 
world’s children.  This includes $4 billion from the International 
Finance Facility for Immunization (IFFIm) over the next 10 years 
and a $750 million investment from the Bill and Melinda Gates 
Foundation for 2006-2015.  Both of these investments will support 
the GAVI Fund for several initiatives including supporting measles 
SIAs, strengthening immunization and health systems, eliminating 
maternal and neonatal tetanus, establishing the polio vaccine 
stockpile, improving access to underused vaccines, and speeding 
the development and introduction of new vaccines in GAVI-eligible 
countries.   Investment cases for introduction of rotavirus vaccine 
and pneumococcal conjugate vaccine are under development. 
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reducing the number of deaths among children under ﬁve in more 
than 70 of the world’s poorest countries.  These funds will be used to 
invest in the introduction of new and underused vaccines including 
combination vaccines for diphtheria, tetanus, pertussis, hepatitis B 
and Haemophilus inﬂuenzae type B (Hib).  It is expected that additional 
vaccines (pneumococcal conjugate, rotavirus, meningococcal 
conjugate, Japanese encephalitis and human papillomavirus) could 
be supported within the next ﬁve years.  Money will also be targeted 
towards strengthening of immunization delivery systems, including 
support for increasing routine immunization coverage in the poorest 
countries and for conducting mass immunization campaigns to 
rapidly reduce mortality from measles and tetanus.  It is estimated 
that this investment will save the lives of ﬁve million children under 
ﬁve by 2015, and a further ﬁve million adult lives after 2015.
To protect children in the United States and reduce the global burden 
of VPDs, the Centers for Disease Control and Prevention (CDC) 
supports a broad range of programmatic and research efforts. 
CDC’s experience working with domestic immunization partners 
provides valuable lessons and linkage with our international efforts 
and priorities. Tremendous progress has been achieved through 
these efforts:
Polio: The number of global polio cases has been reduced by more 
than 99.8% since 1988, including the prevention of ﬁve million cases 
of paralysis and more than 250,000 deaths.  In 2006, only four 
countries remain endemic for polio, the fewest ever.
Measles and Rubella: Endemic measles has been eliminated from 
the Western Hemisphere and no importations from Latin America 
have occurred in the United States since 2000 (in 1990, more than 
90% of measles importations into the U.S. were from Latin America); 
building on this achievement, CDC is working to control measles in 
those parts of the world responsible for importations into the 
United States. 
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CDC is a founding member of the Measles Initiative, which, together 
with host governments, has helped cut measles deaths by 60% in 
Africa from 1999-2004.  Global measles deaths have dropped by 
48%, falling from 871,000 deaths in 1999 to 454,000 in 2004.  CDC is 
also a major partner in regional initiatives in PAHO and the European 
Region of WHO to eliminate rubella and congenital rubella syndrome 
(CRS) by 2010.  In addition, CDC provides technical support to other 
regions and countries in the context of the increasing use of rubella-
containing vaccine from 65 countries in 1996 to 116 
countries in 2004. 
Other VPDs: With technical support from WHO, UNICEF, CDC 
and other partners, global immunization coverage for DTP3 has 
increased from 20% in 1980 to 78% in 2003.  Hepatitis B vaccine 
is now given routinely in 153 countries.  However, approximately 
40,000 immigrants with chronic hepatitis B are admitted each year 
to the United States.  Increasing the number of countries offering 
the vaccine routinely will reduce the burden of HBV infections in 
this country.  CDC support has greatly increased for enhancing 
global inﬂuenza surveillance and promoting wider use of seasonal 
inﬂuenza vaccine both to reduce the burden of inﬂuenza disease 
and to build capacity for pandemic inﬂuenza preparedness and 
response.  Hib vaccine is provided routinely in 92 countries (WHO, 
as of end of 2004).  An opportunity now exists to expand support 
for the introduction of rotavirus, HPV, and pneumococcal vaccine to 
further reduce illness and death in other countries and protect the 
health of children and adults in the United States. 
Linkages with non-vaccine child survival interventions: Immunization 
campaigns are increasingly used as a platform for delivering additional 
child survival interventions.  Through 2005, nearly 18 million doses 
of de-worming medicine and 3.5 million insecticide-treated bed nets 
have been provided during immunization campaigns in Africa.  The 
bed nets already have prevented tens of thousands of childhood 
deaths from malaria. In addition, an estimated 1.25 million childhood 
deaths have been averted by administration of Vitamin A during polio 
immunization campaigns since 1998.
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CDC also actively supports the evaluation and introduction of new 
vaccines to prevent pneumonia, meningitis, and diarrheal illness in 
children, and research to develop new vaccines to protect against 
the greatest killers in developing countries: HIV, tuberculosis, and 
malaria.  In addition, CDC provides support to strengthen routine 
immunization programs and to increase the safety of vaccines 
and injections.
This is a critical moment for CDC to remain deeply engaged in 
global immunization.  To fully realize the beneﬁts of the increased 
interest and support for global immunization, there is an urgent 
need to provide expertise in immunization program implementation, 
epidemiologic and laboratory surveillance of VPDs, technical and 
operational support to strengthen immunization programs, and 
technical support for development, introduction and evaluation 
of new vaccines.  Moreover, CDC can leverage its technical and 
programmatic support and funding to positively inﬂuence the 
support of other global health partners for global immunization. 
CDC shares the established goals of protecting U.S. citizens from 
VPDs and reducing the burden of VPDs in all countries, and it has 
substantial technical expertise to support all aspects of 
global immunization.  
Support for global immunization requires close partnership with other 
international agencies and donors engaged in global immunization, 
including WHO, UNICEF, World Bank, Rotary International, American 
Red Cross, International Federation of Red Cross and Red Crescent 
Societies, the UN Foundation, the Bill and Melinda Gates Foundation, 
and the GAVI Alliance.  CDC will continue to support and expand 
these partnerships to assure the greatest impact of CDC’s technical 
and scientiﬁc resources on reducing the burden of VPDs.
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The most immediate global immunization challenges include: 
 Controlling, eliminating, and/or eradicating VPDs.  This 
challenge includes the goals of certifying global polio 
eradication by 2010 and reducing annual measles deaths by 
90% by 2010 (compared with 2000 ﬁgures).  Progress in global 
immunization will contribute substantially to achievement of 
Millennium Development Goal #4:  “Reducing child mortality by 
two-thirds between 1990 and 2015.”
 Improving global surveillance for VPDs and immunization 
program monitoring. 
 Strengthening and sustaining effective immunization services 
and linking immunization delivery with other priority health 
interventions.
 Developing and supporting the introduction of new 
vaccines to prevent diseases of global health importance, 
including vaccines targeting pneumococcal and epidemic 
meningococcal disease, rotavirus, Japanese encephalitis, 
inﬂuenza and avian ﬂu, malaria, HIV, HPV, and TB.
 Building and sustaining partnerships and collaborations to 
support and promote the availability and use of vaccines 
needed in developing countries.
At the same time, these challenges must be addressed in the 
context of broader health systems challenges, which include:
 the need to support immunization in the face of multiple 
competing health priorities at the national level;
 the need to determine and document the impact of 
immunization on MDGs and the primary causes of mortality 
and morbidity;
 overall deﬁciencies in health systems, particularly health 
management;
 the ﬁnancial sustainability of immunization programs, especially 
for new vaccines; and 
 the introduction of new vaccines while maintaining and 
increasing coverage for current routine EPI.
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The purpose of this strategic plan is to articulate the goals, objectives, 
and strategies of CDC and its global partners for effectively meeting 
these global immunization challenges from 2006-2010.  Achievement 
of these goals will require that CDC work closely and effectively 
with global partners.  This document is intended to build on and 
complement CDC’s previous ﬁve-year plan, Global Immunization 
2002-2006: An Over-Arching Strategy for CDC.   
SUMMARY OF GOALS
Working with global partners, CDC will pursue the following 
major global immunization goals:
GOAL 1: Control, eliminate, and/or eradicate vaccine-preventable
      disease, disability, and death globally.
GOAL 2: Improve global surveillance for VPDs (integrated
      epidemiologic and laboratory surveillance) and health
      information systems for immunization program
      monitoring,and consolidate these structures and
      functions into a Global Framework for Immunization    
      Monitoring and Vaccine Preventable Disease
      Surveillance that can support the immunization
      delivery system.
GOAL 3: Build and sustain safe and effective immunization
      services as a component of health delivery systems,
      and promote opportunities for linking immunization     
      delivery with other priority health interventions.
GOAL 4: Support introduction of new vaccines to prevent
      diseases of global public health importance, by
      assisting in vaccinedevelopment, evaluating vaccine
      safety and efﬁcacy, and assisting countries both in
      making evidence-based decisions and in
      implementation issues.
GOAL 5: Build and strengthen multilateral and bilateral
      partnerships and other collaborative efforts to support   
      availability, equitable access, sustainable ﬁnancing, and
      use of vaccines for all children and adults globally,
      especially in developing countries
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GOALS, OBJECTIVES 
AND STRATEGIES
GOAL 1 
Control, eliminate, and/or eradicate 
vaccine preventable disease, 
disability, and death globally.
OBJECTIVES:
1. End global transmission of polio by 2007, certify global polio 
eradication by 2010, and initiate global action plan for poliovirus 
containment and OPV cessation (Global Action Plan for 
Laboratory Containment of Polioviruses, 3rd edition [GAP III]).  
(GIVS)
2. By 2010, reduce by 90% the annual global measles-related 
mortality compared with the 2000 estimates (2000 baseline: 
734,000 deaths). (GIVS)
2. a. Eliminate measles in EURO by 2010, EMRO by   2010, and 
WPRO by 2012.  Sustain measles elimination in PAHO (target 
achieved in 2002). (WHO Regional Goals)
2. b. By 2010, at least 75% of countries (144 of 192) will have 
achieved >90% ﬁrst dose measles coverage.  (WHO Strategic 
Plan 2006-9)
2. c. By 2010, 100% of countries will have implemented a 
second opportunity for measles immunization within the 
preceding 5 years through routine or supplemental immunization 
activities.  (WHO Strategic Plan 2006-9)
3. Eliminate rubella and congenital rubella syndrome (CRS) in the 
American and European Regions of WHO by 2010 and support 
the control and prevention of rubella and CRS worldwide. 
4. By 2010, all countries will have introduced hepatitis B vaccine in 
infant immunization schedules.  (WHO Strategic Plan 2006-9) 
4. a. EMRO target:  reduce seroprevalence of HBsAg to less 
than 1% in age cohorts born since introduction of routine 
vaccination.
4. b. WPRO target:  By 2012, reduce the seroprevalence of 
HBsAg to less than 2% in 5-year-old children born since 
introduction of routine vaccination (and achieve 80% coverage 
with birth dose within 24 hours of birth). 
5. Eliminate neonatal tetanus (NNT) (< 1 case per 1000 live births) 
in all districts of all countries by 2010.
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STRATEGIES:   
 Provide technical and ﬁnancial support to countries and 
partners for surveillance and vaccination campaigns. 
 Provide technical and ﬁnancial support to partners and 
countries to develop, implement and evaluate disease 
reduction and elimination strategies. 
 Promote the development of case-based surveillance for VPDs, 
with expansion of laboratory networks for viral and bacterial 
diseases. (also for Goal 2)
 Ensure that all countries have access to a WHO accredited 
laboratory that provides accurate virologic and bacteriologic 
data.  (also for Goal 2)
 Complete the research agenda to establish the scientiﬁc basis 
for stopping polio vaccination, modifying vaccination strategies 
to achieve eradication, and implementing safeguards to 
minimize risks in the post-eradication period. 
 Promote wider use of seasonal inﬂuenza vaccine both to 
reduce the burden of inﬂuenza disease and to build capacity 
for pandemic inﬂuenza preparedness and response.
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GOAL 2
 Improve global surveillance for VPDs (integrated 
epidemiologic and laboratory surveillance) and 
health information systems for immunization 
program monitoring, and consolidate these 
structures and functions into a Global 
Framework for Immunization Monitoring and 
Vaccine Preventable Diseases Surveillance that 
can support the immunization delivery system.
OBJECTIVES: 
1. By end of 2006, in collaboration with WHO, ﬁnalize and 
begin implementing the “Global Framework for Immunization 
Program Monitoring and Vaccine Preventable Disease 
Surveillance, 2006-2010”, which outlines a strategic approach 
for strengthening VPD surveillance, laboratory network 
capacity, immunization coverage monitoring, and monitoring of 
other key immunization program performance measures.    
2. By 2010, ensure that 100% of countries have access 
to proﬁcient, accredited laboratories for diagnosis and 
conﬁrmation of polio, measles/ rubella, inﬂuenza, hepatitis B, 
yellow fever (as epidemiologically appropriate), pertussis, and 
diphtheria. 
3. Expand regional and national surveillance of diseases that 
can be prevented by new vaccines and strengthen laboratory 
capacity to monitor the impact of these new vaccines on 
disease patterns and program operations, to provide baseline 
data to inform decisions on new vaccine introduction and 
monitor impact.
4. By 2010, ensure that 90% of national immunization programs 
will have effective surveillance systems and technical support 
to monitor immunization safety.  
5. By 2007, build and maintain an effective VPD surveillance 
system with strong linkages to broader networks designed 
for epidemic preparedness and response such as the 
Global Disease Detection Network (GDD) and Global Alert 
and Response Network (GOARN), as well as the global 
inﬂuenza lab network, enabling the appropriate and timely 
use of vaccines and other control strategies in the context of 
emerging or threatening epidemics.
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STRATEGIES:   
 Maintain certiﬁcation quality surveillance for acute ﬂaccid 
paralysis (AFP).
 Expand existing surveillance systems (including polio and 
measles surveillance) to progress towards effective case-
based surveillance for VPDs, both for existing vaccines and 
those recently or about to be introduced.   (GIVS)
 Expand existing laboratory networks, including the polio and 
measles laboratory networks and other regional and local 
networks such as the Pediatric Bacterial Meningitis Network 
and sentinel surveillance networks for pneumococcal and 
rotavirus vaccines, to include other priority diseases such as 
inﬂuenza and avian ﬂu, pertussis, diphtheria, meningococcal 
disease, Japanese encephalitis, HPV, etc.  (GIVS)
 Strengthen laboratory capacity to establish baseline disease 
burden and  monitor the impact of new vaccines on disease 
patterns (also for Goal 4).   (GIVS)
 Strengthen national and regional public health laboratories 
in developing countries by providing the training, equipment, 
reagents, and quality control procedures needed to sustain 
high quality diagnostics for all VPDs and other priority 
diseases.  (GIVS)
 At the global level, develop new diagnostic tests, tools and 
procedures to improve both ﬁeld-based and laboratory 
conﬁrmation of diagnoses (in partnership with WHO).  (GIVS)
 Strengthen local capacity for data management and analysis 
for decision-making and outbreak detection.  (GIVS)
 Improve coverage monitoring of vaccines and other linked 
health interventions and the use of information at district and 
local levels through strengthening human resource capacity, 
monitoring of the quality of data, and improved tools for data 
compilation, feedback and supervision.  (GIVS)
 Contribute to the development and introduction of better tools 
(e.g., computer software) for monitoring coverage of vaccines 
and linked interventions, vaccine and logistics management, 
and disease surveillance to better support data entry, analysis, 
feedback, and utilization, and to improve program performance 
and management.
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 Establish surveillance and response systems for adverse 
events following immunization, both for existing vaccines 
and for new vaccines as they are introduced into national 
schedules.
 For seasonal and avian inﬂuenza:
o Provide technical and ﬁnancial support to countries 
to establish effective surveillance for inﬂuenza to 
determine burden of disease and to understand the 
epidemiology of inﬂuenza virus circulation in the 
developing world and the tropics.
o Provide technical and ﬁnancial support to countries to 
establish early warning systems for human and avian 
inﬂuenza outbreaks.
o Train rapid response teams to respond to surveillance 
data with timely investigation and containment.
o Promote community involvement in outbreak reporting.
o Encourage countries to establish coordination 
mechanisms between ministries of health and 
agriculture to improve their ability to detect and respond 
to human inﬂuenza outbreaks associated with zoonotic 
transmission.
o Enhance laboratory capacity for rapid diagnosis of 
inﬂuenza.
 Assess and evaluate the usefulness of current systems 
for monitoring VPDs (e.g., Pediatric Bacterial Meningitis 
Surveillance, Integrated Disease Surveillance and Response 
[IDSR] in Africa) and impact of vaccine introduction. 
 Develop innovative/alternative approaches to conducting case-
based sentinel surveillance 
 Improve communication, coordination, and (as needed) sharing 
of surveillance data at country level between the immunization 
program and communicable disease group within Ministries of 
Health.   
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GOAL 3
Build and sustain safe and effective 
immunization services as a component of health 
delivery systems, and promote opportunities for 
linking immunization delivery with other priority 
health interventions.  
OBJECTIVES:
1. (GIVS) By 2010, countries will reach at least 90% national 
vaccination coverage and at least 80% vaccination coverage in 
every district or equivalent administrative unit.
2. By 2010, vaccines are given consistent with safe injection 
practices in all countries, and at least 65% of developing 
countries will be using only auto-disable syringes or needle-
free devices for immunizations.  (WHO Strategic Plan 2006-9)
3. By 2010, at least 5 non-vaccine interventions will be integrated 
with EPI for which consensus guidelines are available at the 
regional level for national program management.   (WHO 
Strategic Plan 2006-9)  (e.g. vitamin A, other micronutrients, 
ITN distribution, de-worming treatments, IMCI)
4. By 2010, at least 4 vaccines will have a global recommendation 
for routine immunization beyond infancy, including new 
vaccines or new indications for existing vaccines.  (WHO 
Strategic Plan 2006-9)
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STRATEGIES:
 Provide support to countries and partners to strengthen key 
components of VPD program management and delivery, 
including the formulation and implementation of comprehensive 
multi-year national plans of action.
 Provide support to countries and partners for monitoring and 
evaluation of VPD programs.
 Promote regular immunization program monitoring at 
local, district, and national levels and provide feedback on 
performance, impediments, and new opportunities to all 
partners.  (GIVS)
 Where appropriate, perform operations research and evaluation 
of “what works” to improve the delivery of immunization, to 
make systems more effective, efﬁcient and equitable, and to 
improve immunization coverage.  (GIVS)
 Expand vaccination beyond the traditional infant target age 
groups (to include older children, adolescents and adults) by 
deﬁning target populations and age groups for vaccination 
appropriate to the national situation, and supporting 
introduction of school immunization laws.  (GIVS)
 Use a combination of approaches to reach everybody targeted 
for immunization, including the Reaching Every District (RED) 
strategy, and evaluate implementation of the RED strategy.
 Assess health and economic impacts of vaccination programs 
by applying standard tools to assess the cost-effectiveness of 
different immunization schedules and strategies in a range of 
demographic, geographic, and epidemiological settings (GIVS).
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 Provide technical support to countries to introduce, sustain, 
and monitor recommended safe injection practices for all 
vaccinations, including the use of autodisable syringes or 
needle-free devices.
 Assist countries in analyzing the economics of their 
immunization program and securing the necessary funding for 
sustainable achievement of the program objectives.
 Support programs to incorporate vitamin A, insecticide-
treated bed nets, de-worming medicine, health education, and 
other appropriate health interventions into routine childhood 
immunization programs.
 With partners, develop standardized methods for monitoring 
and evaluating the efﬁciency, effectiveness and impact of 
combined interventions to improve coverage, and adapt them 
for use at the district and service delivery level. (GIVS) 
 Partner with UNICEF, WHO, and GAVI to address vaccine 
procurement and supply as a global issue, in keeping with 
CDC’s role as a vaccine funding agency.
 Assist in the interpretation of surveillance, disease burden data, 
and planning information for policy development at national, 
regional, and global levels.  
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GOAL 4
Support introduction of new vaccines to prevent 
diseases of global public health importance, by 
assisting in vaccine development, evaluating 
vaccine safety and efﬁcacy, and assisting countries 
both in making evidence-based decisions and in 
implementation issues.
OBJECTIVES:
1. Working with WHO, ensure that within 5 years of introduction 
of a new vaccine into the routine immunization program of 
each country, coverage reaches the same level as that for other 
vaccines given at the same age.  (GIVS)
2. Working with WHO, complete development by 2010 of the 
evidence base, including burden of disease, to assess the 
appropriateness of introduction into immunization programs 
of 5 new vaccines (human papilloma virus [HPV], Japanese 
encephalitis, meningococcal A conjugate, pneumococcal 
conjugate, rotavirus).    (WHO Strategic Plan 2006-9)
3. Working with WHO, establish a network by 2010 of at least 10 
sentinel countries with a monitoring system for AEFIs and post-
marketing surveillance of new vaccines.  (WHO Strategic Plan 
2006-9)
4. Introduce Haemophilus inﬂuenzae type b (Hib) vaccine 
in all countries by 2010, except those in which robust 
epidemiological evidence exists of low disease burden, lack 
of beneﬁt or overwhelming impediments to implementation 
(GAVI, SAGE 2005).   [NOTE: the WHO Strategic Plan 2006-9 
proposes that by 2010, 125 countries will have introduced Hib 
vaccine]
5. By 2010, work with WHO to ensure that all nerve tissue-based 
vaccines for human rabies prevention are replaced by safer, 
more effective, and equally affordable tissue culture products.
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STRATEGIES:
 Collaborate with WHO and other partners on development 
of new vaccines and advocacy for affordable and equitable 
introduction.
 Strengthen country capacity to ensure effective and 
sustainable introduction of new vaccines and technologies 
based on informed decisions.
 Establish surveillance and response systems for adverse 
events following immunization for new vaccines as they are 
introduced into national schedules.
 Strengthen country capacity to assess disease burden and the 
cost and cost-effectiveness of new or underutilized vaccines 
and technologies through the use of standard tools.  (GIVS)
 Ensure effective and sustainable introduction of new vaccines 
and technologies.  (GIVS) 
 Integrate the introduction of each new vaccine into each 
country’s multi-year national plan of action including a ﬁnancial 
analysis.  (GIVS)
 Generate geographically and epidemiologically representative 
clinical data on vaccine effectiveness and conduct post-
licensure evaluations of the impact of vaccination on disease 
patterns and child survival.   (GIVS) 
 Promote research and development of new vaccines against 
diseases of public health importance.  (GIVS)
• Work with partners to expedite evaluation of the efﬁcacy of 
new rotavirus vaccines in settings in Asia and Africa where 
most rotavirus mortality occurs. 
 Encourage countries to strengthen inﬂuenza surveillance 
and vaccination policy development to determine the burden 
of inﬂuenza, the cost-effectiveness of introducing inﬂuenza 
vaccine and its impact, and to decide on the optimal 
vaccination strategy to use.  
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GOAL 5
Build and strengthen multilateral and bilateral 
partnerships and other collaborative efforts 
to support availability, equitable access, 
sustainable ﬁnancing, and use of vaccines for 
all children and adults globally, especially in 
developing countries.
OBJECTIVES:
1. Engage in new and strengthen existing partnerships to 
help achieve our mission (e.g., the new measles-malaria 
partnership), both at the global level as well as regional 
VPD partnerships tailored to the speciﬁc needs and partner 
composition of regions.
2. Enhance capacity of CDC and domestic and international 
partners to support global immunization programs.
3. Coordinate CDC’s vaccine funding through UNICEF and PAHO 
Revolving Fund, and with vaccine manufacturers.
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STRATEGIES:
 Participate in establishing global immunization priorities, goals 
and objectives, including engagement with the GAVI Alliance 
(with partners).
 Collaborate with partners in communicating the value of 
vaccines, and in the dissemination of accurate information 
about the beneﬁts and risks of vaccines and immunization.
 Participate in interagency coordinating committees (ICCs) at 
the regional level and in selected priority countries.
 Work with global partners to secure and maintain the combined 
resources necessary to address global immunization needs. 
 Work with partners to ensure adequate funding for polio 
eradication, measles mortality reduction and regional 
elimination, the Hib Initiative, hepatitis B control, and other 
initiatives.
 With partners, advocate for creation of stockpiles/strategic 
reserves of vaccines to maintain uninterrupted supply, for 
emergency response to outbreaks, and for special purposes 
(e.g., global OPV stockpile).
 Collaborate with partners to advocate for increasing use of 
vaccines in adults (e.g., vaccination of health care workers, 
pneumococcal and inﬂuenza vaccination, Td and Tdap 
boosters, HPV). 
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